Healthcare - Biotechnology - NASDAQ - US
$ 2.27
-7.72 %
$ 476 M
Market Cap
-1.46
P/E
INCOME STATEMENT
95 K
REVENUE
-328 M
OPERATING INCOME
-327 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Allogene Therapeutics, Inc.
| Revenue | 95 K |
| Cost Of Revenue | 243 M |
| Gross Profit | -243 M |
| Operating Expenses | 84.9 M |
| Operating Income | -328 M |
| Other Expenses | -472 K |
| Net Income | -327 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 95 K | 0.2 | 38.5 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 242.9 | 16.7 | 13.1 | 11.5 | 5.0 | 1.5 | 0 |
| Gross Profit | (242.8) | (16.5) | 25.4 | (11.5) | (5.0) | (1.5) | 0 |
| OPERATING INCOME | |||||||
| Operating Expenses | 84.9 | 335.7 | 294.3 | 258.2 | 202.0 | 192.8 | 2 K |
| Selling, General and Administrative Expenses | 71.7 | 79.3 | 74.1 | 65.3 | 57.5 | 41.0 | 2 K |
| Research and Development Expenses | 242.9 | 256.4 | 220.2 | 193.0 | 144.5 | 151.9 | 0 |
| Operating Income | (327.7) | (335.4) | (255.8) | (258.2) | (202.0) | (192.8) | 2 K |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 0 | 0 | 0 | 0 | 0 | 3.4 | 0 |
| Total Other Income | 0.5 | (4.9) | (1.9) | 8.0 | 17.1 | (18.8) | 22 K |
| Pre-Tax Income | (327.3) | (332.6) | (257.0) | (250.2) | (184.9) | (211.6) | 2 K |
| NET INCOME | |||||||
| Tax Provision | 0 | (2.8) | (12.2) | (16.8) | (0.3) | (0.1) | 24 K |
| Net Income | (327.3) | (329.8) | (244.8) | (233.5) | (184.6) | (211.5) | 2 K |
| EPS | 2.09 | 2.3 | 1.8 | 1.94 | 1.83 | 7.31 | 0 |